Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 4 | 4 |
| List of Tables | 6 | 1 |
| List of Figures | 7 | 1 |
| Introduction | 8 | 9 |
| Overview | 8 | 1 |
| Epidemiology | 9 | 1 |
| Etiology, Co-morbidities and Risk Factors | 10 | 1 |
| Genetics | 10 | 1 |
| Psoriatic Arthritis | 10 | 1 |
| Mental Health Disorders | 11 | 1 |
| Metabolic Syndrome, Smoking, Diet and Alcohol Consumption | 11 | 1 |
| Infections | 11 | 1 |
| K ebner Phenomenon | 12 | 1 |
| Other Immune-mediated Diseases | 12 | 1 |
| Pathophysiology | 12 | 1 |
| Diagnosis | 13 | 1 |
| Treatment Options | 13 | 1 |
| Pharmacological Therapies | 14 | 1 |
| Non-pharmacological Therapies | 15 | 1 |
| Combination and Rotational Therapies | 15 | 1 |
| Quality of Life Assessments | 16 | 1 |
| Summary | 16 | 1 |
| Marketed Products | 17 | 11 |
| Overview | 17 | 1 |
| Methotrexate-based Products | 17 | 1 |
| Sandimmune/Neoral (cyclosporine/modified cyclosporine) Novartis | 18 | 1 |
| Soriatane (acitretin) Steifel Laboratories | 19 | 1 |
| Fumaderm (dimethyl fumarate and ethyl fumarate) Biogen Idec | 20 | 1 |
| Humira (adalimumab) Abbvie Inc. | 21 | 1 |
| Enbrel (etanercept) Amgen Inc. | 22 | 1 |
| Remicade (infliximab) Janssen Biotech | 23 | 1 |
| Stelara (ustekinumab) Janssen Biotech | 24 | 1 |
| Marketed Products Heat Map | 25 | 3 |
| Pipeline | 28 | 25 |
| Overview | 28 | 1 |
| Pipeline Size and Distribution by Phase, Molecule Type and Program Type | 29 | 2 |
| Pipeline Distribution by Molecular Target | 31 | 2 |
| Clinical Trial Landscape | 33 | 1 |
| Clinical Trial Duration | 33 | 4 |
| Clinical Trial Size | 37 | 4 |
| Clinical trial failure rates | 41 | 1 |
| Primary and Secondary Endpoints | 42 | 2 |
| Summary of Psoriasis Clinical Trials | 44 | 1 |
| Promising pipeline molecules | 44 | 1 |
| Ixekizumab Eli Lilly | 44 | 1 |
| Xeljanz (tofacitinib) Pfizer | 45 | 1 |
| Brodalumab Amgen | 46 | 1 |
| Apremilast Celgene | 47 | 1 |
| Secukinumab Alcon | 48 | 1 |
| Heat Map for Pipeline Products | 48 | 5 |
| Market Forecast to 2020 | 53 | 15 |
| Overview | 53 | 1 |
| Global Market | 53 | 3 |
| North America | 56 | 1 |
| Treatment Usage Patterns | 56 | 1 |
| Annual Cost of Treatment | 57 | 2 |
| Market Size | 59 | 1 |
| Top Five EU Markets | 60 | 1 |
| Treatment Usage Patterns | 60 | 1 |
| Annual Cost of Treatment | 61 | 1 |
| Market Size | 62 | 1 |
| Japan | 63 | 1 |
| Treatment Usage Patterns | 63 | 1 |
| Annual Cost of Treatment | 64 | 1 |
| Market Size | 65 | 1 |
| Drivers and Barriers for the Systemic Psoriasis Therapeutics Market | 66 | 1 |
| Drivers | 66 | 1 |
| Rising Global Prevalence | 66 | 1 |
| Changes in Patterns of Diagnosis and Treatment | 66 | 1 |
| Potential for Innovative Pipeline to Address Significant Unmet Need | 66 | 1 |
| High Cost of New Market Entries | 66 | 1 |
| Barriers | 66 | 1 |
| Use of Phototherapy | 66 | 1 |
| Loss of Patent Market Exclusivity for Leading Branded Biologics | 66 | 1 |
| Treatment Discontinuation and Limited Treatment Compliance | 67 | 1 |
| Co-development and Licensing deals | 68 | 8 |
| Co-development Deals | 68 | 3 |
| Abbvie Enters into Co-development Agreement with Biotest for Tregalizumab | 71 | 1 |
| Lycera Enters into Research Agreement with Merck &Co. | 71 | 1 |
| LEO Pharma Enters into Research Agreement with 4SC Discovery for Inflammatory Skin Diseases | 71 | 1 |
| Amgen Enters into Co-Development Agreement with AstraZeneca for Five Human Monoclonal Antibodies Including Brodalumab | 71 | 2 |
| Licensing Deals | 73 | 2 |
| Leo Pharma Enters into Licensing Agreement with Virobay for Psoriasis Drug | 75 | 1 |
| Foamix Enters into Licensing Agreement with Dr. Reddy's Labs | 75 | 1 |
| Cipher Pharma Enters into Licensing Agreement with IBSA Institut Biochimique for Betesil Patch | 75 | 1 |
| Phenex Pharma Enters into Licensing Agreement with Janssen Biotech for Retinoid-Acid Receptor-Related Orphan Receptor Gamma t Program | 75 | 1 |
| Appendix | 76 | 26 |
| All Pipeline Drugs by Phase | 76 | 12 |
| Discovery | 76 | 2 |
| Preclinical | 78 | 4 |
| Phase I | 82 | 2 |
| Phase II | 84 | 2 |
| Phase III | 86 | 1 |
| Undisclosed | 87 | 1 |
| Market Forecasts to 2020 | 87 | 5 |
| Major Developed Markets | 87 | 1 |
| US | 88 | 1 |
| UK | 88 | 1 |
| France | 89 | 1 |
| Germany | 89 | 1 |
| Italy | 90 | 1 |
| Spain | 90 | 1 |
| Japan | 91 | 1 |
| Canada | 91 | 1 |
| Abbreviations | 92 | 1 |
| References | 93 | 5 |
| References for Heat Maps | 98 | 2 |
| Marketed Products | 98 | 1 |
| Pipeline products | 98 | 2 |
| Methodology | 100 | 1 |
| Secondary Research | 100 | 1 |
| Therapeutic Landscape | 100 | 1 |
| Contact Us | 100 | 1 |
| Disclaimer | 101 | 1 |